Abstract
Scleroderma is a rare connective tissue disease that is manifested by cutaneous sclerosis and variable systemic involvement [1]. Two categories of scleroderma are known: systemic sclerosis (SSc), characterized by cutaneous sclerosis and visceral involvement, and localized scleroderma (LoS) or morphea which is confined to the skin and/or underlying tissues [1,2].
Publisher
Mapsci Digital Publisher OPC Pvt. Ltd.
Reference20 articles.
1. 1. Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015;90:62-73. PubMed | CrossRef
2. 2. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KE. Editors. Dermatology in General Medicine. 1987;1841-52.
3. 3. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol. 1997;24(1):73-80. PubMed
4. 4. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006;45(5):614-20. PubMed | CrossRef
5. 5. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Derm. 2009;145(5):545-50. PubMed | CrossRef